Pharmabiz

Chugai presents positive data from Part C of phase I/II NXTAGE study of NXT007 in people switching from emicizumab without a washout period at EAHAD Congress

Chugai presents positive data from Part C of phase I/II NXTAGE study of NXT007 in people switching from emicizumab without a washout period at EAHAD Congress: Tokyo Wednesday, Feb ...
Pharmabiz

Astellas reaches settlement agreement with Lupin in Myrbetriq patent litigation

Astellas reaches settlement agreement with Lupin in Myrbetriq patent litigation: Tokyo Wednesday, February 11, 2026, 16:15 Hrs [IST] Astellas Pharma Inc., a global life sciences c ...
Pharmabiz

OneSource and Hikma Pharma partnership secures approval to commercialise generic version of Ozempic in Saudi Arabia

OneSource and Hikma Pharma partnership secures approval to commercialise generic version of Ozempic in Saudi Arabia: Our Bureau, Mumbai Wednesday, February 11, 2026, 14:50 Hrs [IS ...
Pharmabiz

Care.fi raises $8 million in funding to scale AI-driven healthcare revenue cycle management

Care.fi raises $8 million in funding to scale AI-driven healthcare revenue cycle management: Our Bureau, Bengaluru Wednesday, February 11, 2026, 14:40 Hrs [IST] Care.fi, a healthc ...
Pharmabiz

Articulus Surgical raises seed funding to drive market rollout of India-built surgical robotics platform

Articulus Surgical raises seed funding to drive market rollout of India-built surgical robotics platform: Our Bureau, Bengaluru Wednesday, February 11, 2026, 14:20 Hrs [IST] Artic ...
Pharmabiz

ErlySign’s saliva-based oral cancer detection test receives US FDA breakthrough device designation

ErlySign’s saliva-based oral cancer detection test receives US FDA breakthrough device designation: Our Bureau, Mumbai Wednesday, February 11, 2026, 15:45 Hrs [IST] ErlySign, th ...
Pharmabiz

Whatfix doubles down on healthcare with AI-powered suite to erase the EHR burden and enable clinicians to focus on patient care

Whatfix doubles down on healthcare with AI-powered suite to erase the EHR burden and enable clinicians to focus on patient care: Our Bureau, Bengaluru Wednesday, February 11, 2026 ...
Pharmabiz

Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout: Stockholm Wednesday, February 11, 2026, 14:00 Hrs [IST] Swedish Or ...
Pharmabiz

DIFF Biotech’s nasal spray influenza vaccine, DIFF-flu receives China NMPA approval

DIFF Biotech’s nasal spray influenza vaccine, DIFF-flu receives China NMPA approval: Hangzhou, China Wednesday, February 11, 2026, 15:00 Hrs [IST] Zhejiang Difference Biological ...
Pharmabiz

Karma Foundation strengthens animal welfare efforts through advanced veterinary care in India

Karma Foundation strengthens animal welfare efforts through advanced veterinary care in India: Our Bureau, Bengaluru Wednesday, February 11, 2026, 14:10 Hrs [IST] Karma Foundation ...
Pharmabiz

VectorY Therapeutics doses first participant in phase 1/2 PIONEER-ALS trial to evaluate VTx-002 in people with amyotrophic lateral sclerosis

VectorY Therapeutics doses first participant in phase 1/2 PIONEER-ALS trial to evaluate VTx-002 in people with amyotrophic lateral sclerosis: Amsterdam Wednesday, February 11, 202 ...
Pharmabiz

US FDA accepts and grants priority review status to Takeda’s oveporexton for the treatment of narcolepsy type 1

US FDA accepts and grants priority review status to Takeda’s oveporexton for the treatment of narcolepsy type 1: Osaka, Japan Wednesday, February 11, 2026, 12:00 Hrs [IST] Taked ...